

### **III. REMARKS**

#### **A. Status of the Application**

Claims 32-53 are pending herein. Claims 32-53 have been added and prior pending claims 3-8 have been cancelled. Claim 32 corresponds substantially to original claim 11 which was the subject of Group V according to the Office action mailed December 16, 2004.

The present paper is in response to the Final Office Action mailed October 7, 2005 and the Advisory Action mailed November 15, 2005. Reconsideration of this application in light of the following remarks is respectfully requested.

#### **B. Personal Interview Conducted on February 27, 2006**

Applicants' counsel and Mannatech's corporate representative wish to thank Examiners Flood and McKelvey for their time and the courtesies extended during the personal interview conducted on February 27, 2006. As discussed during the interview and as noted on the Interview Summary Record, Applicants will be permitted to invention switch upon the filing of the present Request for Continued Examination.

#### **C. New Claims 32-53**

New claims 32-53 are directed to a method of providing saccharides that involves mixing into a single dose a dietary supplement composition that falls within Group V according to the Office action mailed December 16, 2004. New Claim 32 corresponds substantially to original claim 11. As claimed herein, the dietary supplement composition includes a nutritionally effective amount of purified acetylated mannose, a nutritionally effective amount of a first saccharide source selected from gum ghatti, gum tragacanth, corn starch and arabinogalactan, and a nutritionally effective amount of at least two saccharides selected from galactose, glucose, mannose, xylose, fucose, arabinose, glucuronic acid, galacturonic acid and glucosamine.

Applicants submit that none of the art of record discloses, motivates or suggests the foregoing subject matter.

As discussed during the interview, Applicants are pointing to the exact location in the specification for support for new Claims 32-53. Claims 32-53 are fully supported by the enabling disclosure of the present application and the original claims as filed. In this regard, the Examiners'

attention is directed to Example 5 as well as paragraphs [0073] to [0074] of the present disclosure. Example 5 reads as follows across pages 7 and 8 of United States Patent Application No. 20040171583 A1 as published:

EXAMPLE 5

[0073] The dietary supplement formulation of this example was prepared on large scale according to the above examples. This formulation, referred to as Glyco-1, includes the following ingredients in the amounts indicated. The weight percentage is based upon the weight of the final formulation containing all of the ingredients.

Ingredient	Weight Percent
MANAPOL® (aloe vera extract)	10
gum ghatti	10
gum tragacanth	10
glucosamine	10

-continued

Ingredient	Weight Percent
corn starch	12
arabinogalactan	48

[0074] This composition was formulated into topical and oral preparations as indicated above.

The aloe vera extract listed is one source of purified acetylated mannans. A source for the saccharides from gums include, e.g., gum ghatti and gum tragacanth. Finally, the sources for the sugars include, inter alia, corn starch (e.g., glucose), glucosamine (a saccharide) and arabinogalactan (e.g., arabinose and galactose). Support for the additional sources of gums may be found at, e.g., paragraph [0043] and Table 3, and for the sugars may be found at paragraph [0030] and [0031].


Applicants respectfully request the allowance of claims 32-53.

**CONCLUSION**

In view of the foregoing, it is respectfully submitted that claims 32-53 are in condition for allowance. Should the Examiner deem that an interview with Applicants' undersigned attorney would expedite consideration of claims 32-53, the Examiner is invited to call the undersigned attorney at the telephone number indicated below.

Date: 3/7/06

Respectfully submitted,



Randall C. Brown  
Registration No. 31,213  
Attorney for Applicants

HAYNES AND BOONE, L.L.P.  
901 Main Street, Suite 3100  
Dallas, Texas 75202-3789  
Tel: (214) 651-5242  
Fax: (214) 200-0853